Treatments emerging from the digital therapeutics space were once greeted with optimism, due to the potential to aid patients’ health through technology, rather than pharmaceuticals.
Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder.
Among the many struggles faced by the digital therapeutics industry is the difficulty of designing and running effective clinical trials of digital therapeutics.
Swedish pharma company Vicore has won breakthrough status from the FDA for Almee, a cognitive behavioural therapy (CBT) app used to support people with pulmonary fibrosis
UK healthcare investor RYSE Asset Management has closed a new fund to support start-ups involved in digital health and care technologies, raising $50 million.
Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hype
In vitro gametogenesis (IVG) holds much potential for same-sex couples and women of a more advanced age struggling with infertility, but the question is whether we’re quite there yet.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.